Soleno Therapeutics, Inc. (SLNO)

Ticker: SLNO Exchange: NAS


Loading...
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Soleno Therapeutics, Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
194.88
Quantity 15,603 -5.8%
Value US$3,713,763
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
443.89
Quantity 38,892 -14.3%
Value US$1,520,880
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
397.10
Quantity 8,206 +6.1%
Value US$2,795,936
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
31.72
Quantity 488 -1.2%
Value US$15,479
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
31.04
Quantity 1,838 -4.4%
Value US$57,049
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
30.04
Quantity 4,256 -9.2%
Value US$127,837
Transaction date
Proposed sale
Price
82.15
Quantity 1,347,522
Value US$110,696,581
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
82.76
Quantity 3,830 -22.5%
Value US$316,971
2.0
PATRICIA HIRANO Officer Officer
Transaction date
Proposed sale
Price
82.76
Quantity 3,830
Value US$316,971
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
84.25
Quantity 266 -1.5%
Value US$22,410
2.0
PATRICIA HIRANO Officer Officer
Transaction date
Proposed sale
Price
84.25
Quantity 266
Value US$22,410
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
70.11
Quantity 3,782 -12.3%
Value US$265,156
2.0
PATRICIA HIRANO Officer Officer
Transaction date
Proposed sale
Price
70.11
Quantity 3,782
Value US$265,156
2.8
Pauls Matthew Non-Executive Director
Transaction date
Sale
Price
71.55
Quantity 5,937 -47.7%
Value US$424,797
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
73.60
Quantity 2,691 -8.0%
Value US$198,058
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
69.52
Quantity 9,253 -21.6%
Value US$643,246
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
68.92
Quantity 12,324 -22.4%
Value US$849,386
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
67.46
Quantity 3,394 -5.8%
Value US$228,946
2.0
PATRICIA HIRANO Officer Officer
Transaction date
Proposed sale
Price
69.40
Quantity 27,662
Value US$1,919,636
2.8
Matthew Pauls Officer Officer
Transaction date
Proposed sale
Price
67.39
Quantity 5,937
Value US$400,094
2.9
Vivo Opportunity, LLC Large shareholder
Transaction date
Sale
Price
70.60
Quantity 333,557 -7.0%
Value US$23,549,124
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
67.04
Quantity 37,000 -44.9%
Value US$2,480,436
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
72.64
Quantity 34 -0.1%
Value US$2,470
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
71.74
Quantity 225 -0.5%
Value US$16,142
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
70.73
Quantity 155 -0.3%
Value US$10,964
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
69.84
Quantity 1,505 -3.2%
Value US$105,105
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
68.79
Quantity 2,599 -5.2%
Value US$178,780
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
67.70
Quantity 1,976 -3.8%
Value US$133,777
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
66.79
Quantity 1,087 -2.1%
Value US$72,602
0.8
Manning Meredith Chief Commercial Officer Officer
Transaction date
Sale
Price
65.97
Quantity 668 -1.2%
Value US$44,067
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
70.80
Quantity 8,044 -7.1%
Value US$569,494
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
70.03
Quantity 36,157 -24.2%
Value US$2,531,919
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
69.07
Quantity 25,799 -14.7%
Value US$1,782,022
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
72.64
Quantity 86 -0.1%
Value US$6,247
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
71.74
Quantity 563 -0.5%
Value US$40,391
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
70.73
Quantity 387 -0.4%
Value US$27,374
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
69.84
Quantity 3,762 -3.4%
Value US$262,727
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
68.79
Quantity 6,498 -5.6%
Value US$446,985
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
67.70
Quantity 4,940 -4.1%
Value US$334,441
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
66.79
Quantity 2,717 -2.2%
Value US$181,473
2.5
Mackaness James H CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
65.97
Quantity 1,669 -1.3%
Value US$110,102
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
66.95
Quantity 23,475 -45.5%
Value US$1,571,717
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
66.00
Quantity 50,156 -49.3%
Value US$3,310,080
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
72.64
Quantity 91 -0.1%
Value US$6,610
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
71.74
Quantity 597 -1.0%
Value US$42,831
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
70.73
Quantity 411 -0.7%
Value US$29,072
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
69.84
Quantity 3,990 -6.0%
Value US$278,650
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
68.79
Quantity 6,891 -9.4%
Value US$474,019
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
67.70
Quantity 5,239 -6.7%
Value US$354,684
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
66.79
Quantity 2,881 -3.5%
Value US$192,427
2.0
Yen Kristen SEE REMARKS Officer
Transaction date
Sale
Price
65.97
Quantity 1,769 -2.1%
Value US$116,699
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
70.03
Quantity 10,000 -21.4%
Value US$700,330
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
72.64
Quantity 19 -0.1%
Value US$1,380
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
71.74
Quantity 125 -0.3%
Value US$8,968
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
70.73
Quantity 86 -0.2%
Value US$6,083
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
69.84
Quantity 836 -2.2%
Value US$58,384
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
68.79
Quantity 1,444 -3.7%
Value US$99,330
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
67.70
Quantity 1,098 -2.7%
Value US$74,335
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
66.79
Quantity 604 -1.5%
Value US$40,342
0.7
Huang Michael F. Sr. VP of Clinical Development Officer
Transaction date
Sale
Price
65.97
Quantity 371 -0.9%
Value US$24,475
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
72.50
Quantity 15,145 -21.4%
Value US$1,098,012
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
70.18
Quantity 24,989 -26.1%
Value US$1,753,628
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
67.47
Quantity 24,776 -20.5%
Value US$1,671,629
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Planned sale
Price
66.39
Quantity 46,214 -27.7%
Value US$3,068,147
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
72.64
Quantity 73 -0.1%
Value US$5,303
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
71.74
Quantity 478 -0.5%
Value US$34,293
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
70.73
Quantity 329 -0.3%
Value US$23,272
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
69.84
Quantity 3,198 -3.2%
Value US$223,339
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
68.79
Quantity 5,524 -5.3%
Value US$379,985
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
67.70
Quantity 4,199 -3.9%
Value US$284,275
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
66.79
Quantity 2,310 -2.1%
Value US$154,289
2.0
Hirano Patricia C SEE REMARKS Officer
Transaction date
Sale
Price
65.97
Quantity 1,418 -1.3%
Value US$93,544
2.1
Anish Bhatnagar CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Sale
Price
69.30
Quantity 199,226 -25.7%
Value US$13,805,904
2.1
Anish Bhatnagar CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Sale
Price
67.37
Quantity 8,423 -1.1%
Value US$567,458
2.1
Anish Bhatnagar CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Sale
Price
66.33
Quantity 209,689 -21.1%
Value US$13,908,797
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-03-31 2026-03-27 S Sale

Chief Commercial Officer

Officer
15,603 -5.8%
194.88
US$3,713,763
15,603 -5.8% 194.88 US$3,713,763
2026-03-31 2026-03-27 S Sale

Chief Commercial Officer

Officer
38,892 -14.3%
443.89
US$1,520,880
38,892 -14.3% 443.89 US$1,520,880
2026-03-31 2026-03-27 S Sale

Chief Commercial Officer

Officer
8,206 +6.1%
397.10
US$2,795,936
8,206 +6.1% 397.10 US$2,795,936
2026-03-31 2026-03-27 S Sale

Sr. VP of Clinical Development

Officer
488 -1.2%
31.72
US$15,479
488 -1.2% 31.72 US$15,479
2026-03-31 2026-03-27 S Sale

Sr. VP of Clinical Development

Officer
1,838 -4.4%
31.04
US$57,049
1,838 -4.4% 31.04 US$57,049
2026-03-31 2026-03-27 S Sale

Sr. VP of Clinical Development

Officer
4,256 -9.2%
30.04
US$127,837
4,256 -9.2% 30.04 US$127,837
2025-08-15 2025-08-11 PrS Proposed sale

Shareholder

1,347,522
82.15
US$110,696,581
1,347,522 82.15 US$110,696,581
2025-07-03 2025-07-01 PlS Planned sale

SEE REMARKS

Officer
3,830 -22.5%
82.76
US$316,971
3,830 -22.5% 82.76 US$316,971
2025-07-01 2025-07-01 PrS Proposed sale

Officer

Officer
3,830
82.76
US$316,971
3,830 82.76 US$316,971
2025-06-26 2025-06-24 PlS Planned sale

SEE REMARKS

Officer
266 -1.5%
84.25
US$22,410
266 -1.5% 84.25 US$22,410
2025-06-24 2025-06-24 PrS Proposed sale

Officer

Officer
266
84.25
US$22,410
266 84.25 US$22,410
2025-04-02 2025-04-01 PlS Planned sale

SEE REMARKS

Officer
3,782 -12.3%
70.11
US$265,156
3,782 -12.3% 70.11 US$265,156
2025-04-01 2025-04-01 PrS Proposed sale

Officer

Officer
3,782
70.11
US$265,156
3,782 70.11 US$265,156
2025-03-31 2025-03-28 S Sale Non-Executive Director
5,937 -47.7%
71.55
US$424,797
5,937 -47.7% 71.55 US$424,797
2025-03-31 2025-03-28 PlS Planned sale

SEE REMARKS

Officer
2,691 -8.0%
73.60
US$198,058
2,691 -8.0% 73.60 US$198,058
2025-03-31 2025-03-28 PlS Planned sale

SEE REMARKS

Officer
9,253 -21.6%
69.52
US$643,246
9,253 -21.6% 69.52 US$643,246
2025-03-31 2025-03-28 PlS Planned sale

SEE REMARKS

Officer
12,324 -22.4%
68.92
US$849,386
12,324 -22.4% 68.92 US$849,386
2025-03-31 2025-03-28 PlS Planned sale

SEE REMARKS

Officer
3,394 -5.8%
67.46
US$228,946
3,394 -5.8% 67.46 US$228,946
2025-03-28 2025-03-28 PrS Proposed sale

Officer

Officer
27,662
69.40
US$1,919,636
27,662 69.40 US$1,919,636
2025-03-28 2025-03-28 PrS Proposed sale

Officer

Officer
5,937
67.39
US$400,094
5,937 67.39 US$400,094
2025-03-28 2025-03-28 S Sale Large shareholder
333,557 -7.0%
70.60
US$23,549,124
333,557 -7.0% 70.60 US$23,549,124
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
37,000 -44.9%
67.04
US$2,480,436
37,000 -44.9% 67.04 US$2,480,436
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
34 -0.1%
72.64
US$2,470
34 -0.1% 72.64 US$2,470
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
225 -0.5%
71.74
US$16,142
225 -0.5% 71.74 US$16,142
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
155 -0.3%
70.73
US$10,964
155 -0.3% 70.73 US$10,964
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
1,505 -3.2%
69.84
US$105,105
1,505 -3.2% 69.84 US$105,105
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
2,599 -5.2%
68.79
US$178,780
2,599 -5.2% 68.79 US$178,780
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
1,976 -3.8%
67.70
US$133,777
1,976 -3.8% 67.70 US$133,777
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
1,087 -2.1%
66.79
US$72,602
1,087 -2.1% 66.79 US$72,602
2025-03-31 2025-03-27 S Sale

Chief Commercial Officer

Officer
668 -1.2%
65.97
US$44,067
668 -1.2% 65.97 US$44,067
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
8,044 -7.1%
70.80
US$569,494
8,044 -7.1% 70.80 US$569,494
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
36,157 -24.2%
70.03
US$2,531,919
36,157 -24.2% 70.03 US$2,531,919
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
25,799 -14.7%
69.07
US$1,782,022
25,799 -14.7% 69.07 US$1,782,022
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
86 -0.1%
72.64
US$6,247
86 -0.1% 72.64 US$6,247
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
563 -0.5%
71.74
US$40,391
563 -0.5% 71.74 US$40,391
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
387 -0.4%
70.73
US$27,374
387 -0.4% 70.73 US$27,374
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
3,762 -3.4%
69.84
US$262,727
3,762 -3.4% 69.84 US$262,727
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
6,498 -5.6%
68.79
US$446,985
6,498 -5.6% 68.79 US$446,985
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
4,940 -4.1%
67.70
US$334,441
4,940 -4.1% 67.70 US$334,441
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
2,717 -2.2%
66.79
US$181,473
2,717 -2.2% 66.79 US$181,473
2025-03-31 2025-03-27 S Sale

CHIEF FINANCIAL OFFICER

Officer
1,669 -1.3%
65.97
US$110,102
1,669 -1.3% 65.97 US$110,102
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
23,475 -45.5%
66.95
US$1,571,717
23,475 -45.5% 66.95 US$1,571,717
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
50,156 -49.3%
66.00
US$3,310,080
50,156 -49.3% 66.00 US$3,310,080
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
91 -0.1%
72.64
US$6,610
91 -0.1% 72.64 US$6,610
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
597 -1.0%
71.74
US$42,831
597 -1.0% 71.74 US$42,831
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
411 -0.7%
70.73
US$29,072
411 -0.7% 70.73 US$29,072
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
3,990 -6.0%
69.84
US$278,650
3,990 -6.0% 69.84 US$278,650
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
6,891 -9.4%
68.79
US$474,019
6,891 -9.4% 68.79 US$474,019
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
5,239 -6.7%
67.70
US$354,684
5,239 -6.7% 67.70 US$354,684
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
2,881 -3.5%
66.79
US$192,427
2,881 -3.5% 66.79 US$192,427
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
1,769 -2.1%
65.97
US$116,699
1,769 -2.1% 65.97 US$116,699
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
10,000 -21.4%
70.03
US$700,330
10,000 -21.4% 70.03 US$700,330
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
19 -0.1%
72.64
US$1,380
19 -0.1% 72.64 US$1,380
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
125 -0.3%
71.74
US$8,968
125 -0.3% 71.74 US$8,968
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
86 -0.2%
70.73
US$6,083
86 -0.2% 70.73 US$6,083
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
836 -2.2%
69.84
US$58,384
836 -2.2% 69.84 US$58,384
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
1,444 -3.7%
68.79
US$99,330
1,444 -3.7% 68.79 US$99,330
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
1,098 -2.7%
67.70
US$74,335
1,098 -2.7% 67.70 US$74,335
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
604 -1.5%
66.79
US$40,342
604 -1.5% 66.79 US$40,342
2025-03-31 2025-03-27 S Sale

Sr. VP of Clinical Development

Officer
371 -0.9%
65.97
US$24,475
371 -0.9% 65.97 US$24,475
2025-03-31 2025-03-27 PlS Planned sale

SEE REMARKS

Officer
15,145 -21.4%
72.50
US$1,098,012
15,145 -21.4% 72.50 US$1,098,012
2025-03-31 2025-03-27 PlS Planned sale

SEE REMARKS

Officer
24,989 -26.1%
70.18
US$1,753,628
24,989 -26.1% 70.18 US$1,753,628
2025-03-31 2025-03-27 PlS Planned sale

SEE REMARKS

Officer
24,776 -20.5%
67.47
US$1,671,629
24,776 -20.5% 67.47 US$1,671,629
2025-03-31 2025-03-27 PlS Planned sale

SEE REMARKS

Officer
46,214 -27.7%
66.39
US$3,068,147
46,214 -27.7% 66.39 US$3,068,147
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
73 -0.1%
72.64
US$5,303
73 -0.1% 72.64 US$5,303
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
478 -0.5%
71.74
US$34,293
478 -0.5% 71.74 US$34,293
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
329 -0.3%
70.73
US$23,272
329 -0.3% 70.73 US$23,272
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
3,198 -3.2%
69.84
US$223,339
3,198 -3.2% 69.84 US$223,339
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
5,524 -5.3%
68.79
US$379,985
5,524 -5.3% 68.79 US$379,985
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
4,199 -3.9%
67.70
US$284,275
4,199 -3.9% 67.70 US$284,275
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
2,310 -2.1%
66.79
US$154,289
2,310 -2.1% 66.79 US$154,289
2025-03-31 2025-03-27 S Sale

SEE REMARKS

Officer
1,418 -1.3%
65.97
US$93,544
1,418 -1.3% 65.97 US$93,544
2025-03-31 2025-03-27 S Sale

CHIEF EXECUTIVE OFFICER

Executive Director
199,226 -25.7%
69.30
US$13,805,904
199,226 -25.7% 69.30 US$13,805,904
2025-03-31 2025-03-27 S Sale

CHIEF EXECUTIVE OFFICER

Executive Director
8,423 -1.1%
67.37
US$567,458
8,423 -1.1% 67.37 US$567,458
2025-03-31 2025-03-27 S Sale

CHIEF EXECUTIVE OFFICER

Executive Director
209,689 -21.1%
66.33
US$13,908,797
209,689 -21.1% 66.33 US$13,908,797

See older Soleno Therapeutics, Inc. insider trades

Plus unlocks the full transaction history.

See localized pricing at checkout
Unlock Soleno Therapeutics, Inc. history with Plus

Billed monthly · Cancel anytime